Our approach to funding is to support exceptional research that covers a wide range of themes including understanding the causes of primary bone cancer, developing new ways to diagnose and identifying new ways to treat primary bone cancer.
Our 2022-2032 strategy Accelerating Research to Help More Patients Survive and Thrive marks our continued commitment to turn the tide on this disease by pledging £10 million to support innovative and impactful research, wherever this may take place. This research strategy will see us not only focus on improving survival rates but also the quality of life for those who survive. We will capitalise on the progress we have made over recent years, ensure patients remain at the heart of everything we do and remain committed until there’s a cure.
We are committed to funding the highest quality research in a fair and transparent manner, our Peer Review Policy can be found here
We adhere to AMRC's best practices and their six principles of expert review.
All research funding decisions and recommendations are made by BCRT’s Independent Scientific Advisory Panel ISAP.
Application and review overview:
Submission:
- Research applications are submitted by Principal Investigators (PI’s) to a deadline date.
Processing:
- All applications received, acknowledged and assigned an internal research reference .
- They are initially triaged against the eligibility criteria. Any applications which do not meet the eligibility criteria are returned to the PI and host institution with an explanation of where the application was ineligible.
Expert review:
- Eligible applications are assigned to peer reviewers, either internal or external.
- Members of BCRT's PPI panel provide lay reviews.
- Applications are discussed and ranked by ISAP.
Final decision:
- Following the decision making meeting of BCRT’s ISAP, their recommendations are presented to the Board of Trustees for approval
- All applicants receive anonymised feedback on their applications.